Co-Amoxiclav Induced Immune Haemolytic Anaemia: A Case Report
| Autor: | A H N Fernando, V Ratnamalala, H G C S Karunathilaka, Priyanga Ranasinghe, D P Chandrasiri |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Drug
medicine.medical_specialty Blood transfusion media_common.quotation_subject medicine.medical_treatment Case Report 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Diseases of the blood and blood-forming organs media_common biology business.industry Autoantibody General Medicine Haemolysis Discontinuation Naranjo Adverse Drug Reaction Probability Scale 030220 oncology & carcinogenesis biology.protein RC633-647.5 Antibody Complication business 030215 immunology |
| Zdroj: | Case Reports in Hematology Case Reports in Hematology, Vol 2020 (2020) |
| ISSN: | 2090-6579 2090-6560 |
| DOI: | 10.1155/2020/9841097 |
| Popis: | Drug-induced immune haemolytic anaemia (DIIHA) is extremely rare. We herein report a case of DIIHA due to co-amoxiclav. A 53-year-old male being treated for left-sided pyelonephritis with intravenous co-amoxiclav developed symptoms and signs of anaemia on the third day of treatment. He was found to have evidence of haemolysis with a positive Coombs test and IgG antibodies and C3d. Co-amoxiclav was identified as the probable culprit, using the Naranjo adverse drug reaction probability scale. Upon discontinuation of the drug and blood transfusion, the patient’s haematological parameters stabilised. Steroids were not required in the treatment. Diagnosis of DIIHA is made through a history of intake of co-amoxiclav, clinical and laboratory features of haemolysis, and a positive Coombs test. An autoantibody screen is most commonly negative. It is essential for clinicians to be aware about this rare complication caused by commonly prescribed drugs and be able to accurately diagnose and initiate treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|